FUJIFILM Diosynth Biotechnologies (FDB) has completed the first phase of expansion at its manufacturing facility in Hillerød, Denmark, bringing new production capacity into operation.
FDB is a contract development and manufacturing organisation (CDMO) that produces biologics, vaccines, advanced therapies, and oncolytic viruses.
The expansion will add six mammalian cell bioreactors, bringing the site’s total capacity to 12 x 20,000 L bioreactors.
The next phase, which will include an additional 8 x 20,000 L bioreactors and two downstream processing streams, will be supported by a previously announced investment.
The fill/finish production at the site is planned to begin by mid-2025, with full expansion expected to be operational by 2026.
It will extend the site footprint to nearly 51,500m² and create up to 2,200 jobs, said FDB.
FUJIFILM Diosynth Biotechnologies senior vice president and site head Christian Houborg said: “Our operations in Hillerød represent our commitment to being the world-leading partner for life, supporting our customers and their patients globally.
“This expansion is a testament to our vision for introducing robust capabilities into the global biopharma landscape, ensuring the timely delivery of critical therapies to those in need.”
FDB’s parent organisation FUJIFILM has invested more than $8bn since 2011, to establish a global network for biologics manufacturing.
The company plans to begin operations at the first phase of its large-scale production facility in Holly Springs, North Carolina, in 2025.
Also, the expansion is in line with its sustainability initiative, Partners for the Planet, which incorporates sustainable practices across all facilities, said FDB.
Furthermore, the Hillerød site has signed a ten-year power purchase agreement (PPA) to source all electricity from renewable sources.
FUJIFILM Diosynth Biotechnologies president and CEO Lars Petersen said: “The Hillerød facility is the first expansion in our global network, which will include further developments in the US, UK, and Japan.
“By investing in state-of-the-art facilities on both sides of the Atlantic and prioritising our workforce, we are uniquely positioned to meet the evolving needs of our partners and the patients they serve.
“This is just the beginning. With our Partners for Life strategy, we are dedicated to fulfilling our promises and ensuring that our global network supports the production of the life-impacting medicines that make patients’ lives better.”
Recently, FDB signed an agreement with TG Therapeutics for a multi-year manufacturing supply of Briumvi for relapsing forms of multiple sclerosis (RMS).
